Floatz logo

Pyridostigmine

Myalgic Encephalomeyelitis/Chronic Fatigue Syndrome

Brigham and Women's HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Myalgic Encephalomeyelitis/Chronic Fatigue Syndrome cohort.

Asset / SponsorPhaseRating
.Gamma.-Hydroxybutyrate Sodium Salt
University of Medicine and Dentistry of New Jersey
Phase 4B
Noramitriptyline
Duke University
Phase 2B
Naltrexone
Brigham and Women's Hospital
Phase 2CCC
Autologous Leukocytes, 89Zr-Oxine Labeled
University of Alabama at Birmingham
Phase 1CC
Ribavirin
Aarhus University Hospital
N/AD
Citalopram
Vrije Universiteit Brussel
N/AD

Same molecule, other indications

Pyridostigmine is also rated in:

deliriumActive
BB
Indicative · Phase 4
65 / 100
View asset →
strabismusActive
BB
Indicative · Phase 4
65 / 100
View asset →
childhood acute lymphoblastic leukemiaActive
B
Indicative · Phase 4
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →